“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in SEK
Last close As at 26/05/2023
SEK8.30
▲ −0.68 (−7.57%)
Market capitalisation
SEK430m
Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD).
PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.
Managing Director - Head of Content, Healthcare
Viktor Siewertz
CFO
Forecast net cash (SEKm)
51.6
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (20.2) | (14.0) | (78.0) |
| Relative | (18.6) | (12.9) | (78.7) |
| 52 week high/low | SEK41.8/SEK8.3 |
IRLAB has announced an agreement with the McQuade Center for Strategic Research and Development (MSRD), a member of the Otsuka family of pharmaceutical companies. As part of this agreement, MSRD will evaluate IRLAB’s neuropsychiatric preclinical programmes: IRL757 (apathy) and IRL942 (cognitive function). MSRD searches for, identifies and funds innovative early-stage R&D programmes that it believes have the potential to build the future portfolio of Otsuka products. We view this external interest from MSRD as encouraging for IRLAB’s preclinical portfolio; discussions are expected in coming months regarding a potential R&D collaboration for these programmes.
| Y/E Dec | Revenue (SEKm) | EBITDA (SEKm) | PBT (SEKm) | EPS (öre) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 207.9 | 56.1 | 91.1 | 176.0 | 4.7 | 8.2 |
| 2022A | 61.3 | (108.3) | (113.1) | (218.0) | N/A | N/A |
| 2023E | 0.2 | (205.1) | (208.4) | (402.0) | N/A | N/A |
| 2024E | 0.2 | (187.0) | (190.2) | (367.0) | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
